12:00 AM
Oct 27, 2014
 |  BioCentury  |  Emerging Company Profile

Vasomune: Lassoing Tie2

Vasomune's vasculotide activates Tie2 to treat acute kidney injury

Agonizing Tie2 could restore vascular integrity and limit tissue damage in kidney injury, but bringing together the four copies needed to activate the receptor is a job too big for small molecules or antibodies. Vasomune Therapeutics Inc. has shown its four-armed peptidomimetic, vasculotide, activates Tie2 and restores vascular integrity in mouse models.

"Many renal diseases are ultimately characterized by a loss in vascular integrity that damages tubules in the kidney," CEO Parimal Nathwani said. "Our idea is to use vasculotide to fix the problem and restore normal vascular integrity before it gets out of control."

Tyrosine kinase receptor 2 (Tie2) is expressed primarily on endothelial cells and maintains vascular integrity through competing interactions with two of its ligands: angiopoietin 1 (ANG1; ANGPT1), which activates it; and ANG2, which antagonizes it.

In patients with sepsis and acute kidney injury (AKI), circulating levels of ANG2 correlate with disease...

Read the full 750 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >